All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-002054-55 | A phase II Clinical Trial of PXD101 in Patients with Advanced Multiple Myeloma | 2007-01-02 | due-trials |
| Completed, but no date, and reported results | 2005-001474-27 | A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma | bad-data | |
| Exempt, with results | 2005-002338-36 | A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients with Advanced Solid Tumours | 2008-09-15 | not-yet-due |
| Exempt | 2005-002943-23 | Ensayo clínico en fase I-II de Topotect (dexrazoxano) y dosis altas de etopósido en el tratamiento de pacientes adultos con tumores cerebrales sólidos, primarios o secundarios. | not-yet-due | |
| Not reported | 2005-006157-24 | A multicenter open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma | 2011-09-22 | due-trials |
| Not reported | 2006-000220-14 | A therapeutic and pharmacokinetic study of Savene (dexrazoxane) in the treatment of accidental anthracycline extravasation | 2007-05-30 | due-trials |
| Not reported | 2006-000910-19 | A multi-centre, two-stage, open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with advanced melanoma. | 2011-03-24 | due-trials |
| Reported results | 2006-001886-40 | A randomized, double-blind, placebo-controlled parallel group study to assess the safety and efficacy of a new oral formulation of 2-propyl pentanoic acid (2-PPA, PEAC minitablets) for the treatment o... | 2008-09-16 | due-trials |
| Exempt | 2006-002850-31 | APO866 for B-Cell Leukaemia. An open phase I/II clinical study assessing the safety and tolerability of APO866 in patients with refractory B-cell lymphocytic leukaemia not amenable to allogeneic hemop... | 2008-02-02 | not-yet-due |
| Exempt, with results | 2006-004345-42 | A Phase I/II Clinical Trial of PXD101 in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas | 2012-10-29 | not-yet-due |
| Exempt, with results | 2007-000241-35 | A Phase I/II Clinical Trial of PXD101 in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy | 2009-11-27 | not-yet-due |
| Reported results | 2007-000418-35 | A double-blind, randomised, parallel group, placebo-controlled dose finding Phase II study to compare the efficacy and safety of topically applied Avugane™ of different concentrations in subjects with... | 2008-08-22 | due-trials |
| Reported results | 2007-001396-11 | A Phase II Clinical Trial of PXD101 in Patients with Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas | 2009-07-16 | due-trials |
| Reported results | 2008-005843-40 | A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma | 2014-10-27 | due-trials |
| Reported results | 2008-005865-67 | An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carc... | 2012-12-31 | due-trials |